Bristol-Myers Squibb Co. and Meso Scale Discovery said Wednesday they will work together to develop diagnostic tests that measure cerebrospinal fluid biomarkers for use in research of Alzheimer's disease.
The companies did not disclose terms of their collaboration, and said they plan to release the assays they develop during the second quarter.
Meso Scale Discovery is a unit of Gaithersburg, Md.-based Meso Scale Diagnostics LLC.
Shares of Bristol-Myers Squibb fell 11 cents to $33.56 in afternoon trading.